Brendan Flannery
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
Brendan Flannery has a total of 566 co-authors. Here are the top co-authors by number of shared publications:
- Edward A. Belongia
Marshfield Clinic Research Institute , Marshfield, Wisconsin
18 shared publications - Richard Kent Zimmerman
University of Pittsburgh
17 shared publications Manjusha Gaglani
Baylor Scott & White Health, Temple, TX, USA
16 shared publicationsAlicia M. Fry
Influenza Division, Centers for Disease Control and Prevention, Atlanta, USA
12 shared publications- Emily Toth Martin
Department of Epidemiology, University of Michigan School of Public health
12 shared publications - Manjusha Gaglani
Baylor Scott & White Health , Temple, TX
12 shared publications
Latest Publications
- Open Access
Comparative immunogenicity and relative vaccine efficacy of recombinant and cell culture-based influenza vaccines: Results from a randomized trial of adults in the United States, 2024-2025
Background: Recombinant (RIV) and cell culture-based inactivated (ccIIV) influenza vaccines could improve seasonal influenza prevention; however, evidence is limited in how protection may differ among non-egg-based vaccines. Methods: We conducted a randomized trial of RIV versus ccIIV to compare vaccine immunogenicity in adults aged 18 to 64 years during the 2024-25 influenza season (ClinicalTrials.gov, NCT06518577 ). Active surveillance for influenza-like illness was conducted for six months post-vaccination and cumulative incidence of influenza by vaccine type was compared to estimate relative vaccine efficacy. Participants were tested for influenza by reverse-transcription polymerase chain reaction or rapid antigen tests. Immunogenicity was evaluated by hemagglutination inhibition (HAI), virus microneutralization (MN), and neuraminidase inhibition (NAI) assays in a subset of blood specimens collected pre-vaccination and one-month post-vaccination. Results: Among the 591 participants, 25 cases of influenza A were detected; 2.4% cumulative incidence among RIV recipients versus 6.1% among ccIIV recipients. The probability of influenza was 61% lower with RIV than ccIIV (95% confidence interval: 7 to 84). Among 151 participants, post-vaccination HAI and MN titers vaccine components were higher among RIV recipients while NAI titers were higher among ccIIV recipients. Conclusions: RIV provided better protection than ccIIV against influenza A illness in adults during the U.S. 2024-2025 season.
Open AccessComparative immunogenicity and relative vaccine efficacy of recombinant and cell culture-based influenza vaccines: Results from a randomized trial of adults in the United States, 2024-2025
Background: Recombinant (RIV) and cell culture-based inactivated (ccIIV) influenza vaccines could improve seasonal influenza prevention; however, evidence is limited in how protection may differ among non-egg-based vaccines. Methods: We conducted a randomized trial of RIV versus ccIIV to compare vaccine immunogenicity in adults aged 18 to 64 years during the 2024-25 influenza season (ClinicalTrials.gov, NCT06518577 ). Active surveillance for influenza-like illness was conducted for six months post-vaccination and cumulative incidence of influenza by vaccine type was compared to estimate relative vaccine efficacy. Participants were tested for influenza by reverse-transcription polymerase chain reaction or rapid antigen tests. Immunogenicity was evaluated by hemagglutination inhibition (HAI), virus microneutralization (MN), and neuraminidase inhibition (NAI) assays in a subset of blood specimens collected pre-vaccination and one-month post-vaccination. Results: Among the 591 participants, 25 cases of influenza A were detected; 2.4% cumulative incidence among RIV recipients versus 6.1% among ccIIV recipients. The probability of influenza was 61% lower with RIV than ccIIV (95% confidence interval: 7 to 84). Among 151 participants, post-vaccination HAI and MN titers vaccine components were higher among RIV recipients while NAI titers were higher among ccIIV recipients. Conclusions: RIV provided better protection than ccIIV against influenza A illness in adults during the U.S. 2024-2025 season.
- 17 July 2026
- Published by Oxford University Press (OUP) in The Journal of Infectious Diseases
Influenza Antibody Levels Associated With Laboratory-Confirmed Influenza in a Test-Negative Study Design, US Flu Vaccine Effectiveness Network, November 2018 to May 2019
Background: We assessed associations between antibody concentrations within 7 days of symptom onset and testing positive for influenza virus infection among outpatients enrolled in a test-negative study. Methods: From November 2018 to May 2019, study sites in 5 states obtained serum and respiratory specimens from outpatients aged ≥18 years presenting with acute respiratory illness. Respiratory specimens were tested for influenza virus, and viral clades were identified by means of genomic sequencing. We measured influenza antibody titers against vaccine and circulating viruses by means of hemagglutination inhibition (HI), microneutralization (MN) and neuraminidase inhibition (NAI) assays. Reduction in the odds of influenza-associated illness at increasing HI, MN, and NAI antibody titers was estimated using logistic regression, adjusting for influenza vaccination status and time since the beginning of influenza season. Results: Among 175 patients with influenza virus infection, including 112 with influenza A(H1N1)pdm09 and 63 with A(H3N2) (44 clade 3C.3a), and 130 test-negative control patients, higher HI, MN, and NAI antibody titers against circulating influenza viruses were associated with lower odds of confirmed influenza. The odds of A(H1N1)pdm09 infection were 44% and 54% lower for each 2-fold increase in A(H1N1)pdm09 HI or NAI titer, respectively. The odds of A(H3N2) infection were 49% and 28% lower, respectively, for each 2-fold increase in MN or NAI titer against circulating A(H3N2) virus clade. NAI titers were independently associated with lower odds of influenza A(H1N1)pdm09 and A(H3N2) after controlling for HI titer. Conclusions: Higher influenza antibody titers against circulating viruses were associated with lower likelihood of influenza virus infection among adult patients with acute respiratory illness.
- 17 July 2026
- Published by Oxford University Press (OUP) in The Journal of Infectious Diseases
Influenza Antibody Levels Associated With Laboratory-Confirmed Influenza in a Test-Negative Study Design, US Flu Vaccine Effectiveness Network, November 2018 to May 2019
Background: We assessed associations between antibody concentrations within 7 days of symptom onset and testing positive for influenza virus infection among outpatients enrolled in a test-negative study. Methods: From November 2018 to May 2019, study sites in 5 states obtained serum and respiratory specimens from outpatients aged ≥18 years presenting with acute respiratory illness. Respiratory specimens were tested for influenza virus, and viral clades were identified by means of genomic sequencing. We measured influenza antibody titers against vaccine and circulating viruses by means of hemagglutination inhibition (HI), microneutralization (MN) and neuraminidase inhibition (NAI) assays. Reduction in the odds of influenza-associated illness at increasing HI, MN, and NAI antibody titers was estimated using logistic regression, adjusting for influenza vaccination status and time since the beginning of influenza season. Results: Among 175 patients with influenza virus infection, including 112 with influenza A(H1N1)pdm09 and 63 with A(H3N2) (44 clade 3C.3a), and 130 test-negative control patients, higher HI, MN, and NAI antibody titers against circulating influenza viruses were associated with lower odds of confirmed influenza. The odds of A(H1N1)pdm09 infection were 44% and 54% lower for each 2-fold increase in A(H1N1)pdm09 HI or NAI titer, respectively. The odds of A(H3N2) infection were 49% and 28% lower, respectively, for each 2-fold increase in MN or NAI titer against circulating A(H3N2) virus clade. NAI titers were independently associated with lower odds of influenza A(H1N1)pdm09 and A(H3N2) after controlling for HI titer. Conclusions: Higher influenza antibody titers against circulating viruses were associated with lower likelihood of influenza virus infection among adult patients with acute respiratory illness.
- Open Access
Influenza vaccine effectiveness against outpatient acute respiratory illness with laboratory-confirmed influenza, United States, 2024–25 season
Background: Influenza A(H1N1)pdm09 and A(H3N2) viruses predominated during the 2024–25 U.S. influenza season. We estimated influenza vaccine effectiveness (VE) in the United States against mild-to-moderate outpatient influenza illness by influenza type and subtype in the 2024–25 season. Methods: We enrolled outpatients aged ≥8 months with acute respiratory illness symptoms including cough in 7 states. Upper respiratory specimens were tested for influenza type/subtype by reverse-transcriptase polymerase chain reaction (RT-PCR). Influenza VE was estimated with a test-negative design comparing odds of testing positive for influenza among vaccinated versus unvaccinated participants controlling for age, study site, underlying health status, and month of illness onset. We also estimated VE of current season vaccination among adults stratified by prior season vaccination status. Results: Among 6,793 enrolled patients, 2,016 (30%) tested positive for influenza including 961 A(H3N2), 770 A(H1N1)pdm09, and 183 B/Victoria. Overall vaccine effectiveness against any influenza illness was 33% (95% Confidence Interval [CI]: 24 to 41): 27% (95% CI: 14 to 39) against influenza A(H3N2), 37% (95% CI: 24 to 48) against A(H1N1)pdm09, and 40% (95% CI: 12 to 59) against B/Victoria. VE did not differ based on whether or not participants had received influenza vaccine the previous season. Conclusions: Influenza vaccination during the 2024–25 season protected against circulating influenza viruses, reducing the risk of outpatient medically attended influenza overall by approximately one-third among people who were vaccinated. Key Points: Influenza vaccine reduced the risk of outpatient acute respiratory illness due to laboratory-confirmed influenza during the 2024–25 season by a third.
Open AccessInfluenza vaccine effectiveness against outpatient acute respiratory illness with laboratory-confirmed influenza, United States, 2024–25 season
Background: Influenza A(H1N1)pdm09 and A(H3N2) viruses predominated during the 2024–25 U.S. influenza season. We estimated influenza vaccine effectiveness (VE) in the United States against mild-to-moderate outpatient influenza illness by influenza type and subtype in the 2024–25 season. Methods: We enrolled outpatients aged ≥8 months with acute respiratory illness symptoms including cough in 7 states. Upper respiratory specimens were tested for influenza type/subtype by reverse-transcriptase polymerase chain reaction (RT-PCR). Influenza VE was estimated with a test-negative design comparing odds of testing positive for influenza among vaccinated versus unvaccinated participants controlling for age, study site, underlying health status, and month of illness onset. We also estimated VE of current season vaccination among adults stratified by prior season vaccination status. Results: Among 6,793 enrolled patients, 2,016 (30%) tested positive for influenza including 961 A(H3N2), 770 A(H1N1)pdm09, and 183 B/Victoria. Overall vaccine effectiveness against any influenza illness was 33% (95% Confidence Interval [CI]: 24 to 41): 27% (95% CI: 14 to 39) against influenza A(H3N2), 37% (95% CI: 24 to 48) against A(H1N1)pdm09, and 40% (95% CI: 12 to 59) against B/Victoria. VE did not differ based on whether or not participants had received influenza vaccine the previous season. Conclusions: Influenza vaccination during the 2024–25 season protected against circulating influenza viruses, reducing the risk of outpatient medically attended influenza overall by approximately one-third among people who were vaccinated. Key Points: Influenza vaccine reduced the risk of outpatient acute respiratory illness due to laboratory-confirmed influenza during the 2024–25 season by a third.
- Open Access
Influenza Antibody Levels Associated with Laboratory-Confirmed Influenza in a Test-Negative Study Design, US Flu VE Network, November 2018–May 2019
Background: We assessed associations between antibody concentrations within 7 days of symptom onset and testing positive for influenza virus infection among outpatients enrolled in a test-negative study. Methods: From November 2018─May 2019, study sites in five states obtained serum and respiratory specimens from outpatients aged ≥18 years presenting with acute respiratory illness. Respiratory specimens were tested for influenza virus, and viral clades were identified by genomic sequencing. We measured influenza antibody titers against vaccine and circulating viruses by hemagglutination inhibition (HI), microneutralization (MN) and neuraminidase inhibition (NAI) assays. Percent of patients with HI, MN and NAI titers ≥10 and ≥40 were compared among patients with and without influenza-associated illness, and reduction in odds of confirmed influenza at increasing HI, MN and NAI antibody titers was estimated using logistic regression adjusting for influenza vaccination status and time since beginning of influenza season. Results: Among 175 patients with confirmed influenza virus infection, including 112 with influenza A(H1N1)pdm09 and 63 with A(H3N2) (44 clade 3C.3a), and 130 test-negative control patients, higher antibody titers against influenza hemagglutinin or neuraminidase proteins at enrollment were associated with lower odds of influenza virus infection. HI and MN antibody titers against circulating viruses were more strongly associated with protection than titers against vaccine reference viruses. Odds of A(H1N1)pdm09 infection were 44% and 54% lower for each two-fold increase in A(H1N1)pdm09 HI or NAI titer, respectively. Odds of A(H3N2) infection were 46% and 30% lower, respectively, for each two-fold increase in MN or NAI titer against circulating A(H3N2) virus clade. NAI titers were independently associated with lower odds of influenza A(H1N1)pdm09 and A(H3N2) after controlling for HI titer. Conclusion: Higher influenza antibody titers against circulating viruses were associated with lower likelihood of influenza virus infection among adult patients with acute respiratory illness. SUMMARY: From November 2018─May 2019, we assessed the association between antibody concentrations during acute illness and laboratory-confirmed influenza among adult patients enrolled in a test-negative study in five US states. We found that higher influenza antibody titers were associated with lower likelihood of symptomatic influenza virus infection.
Open AccessInfluenza Antibody Levels Associated with Laboratory-Confirmed Influenza in a Test-Negative Study Design, US Flu VE Network, November 2018–May 2019
Background: We assessed associations between antibody concentrations within 7 days of symptom onset and testing positive for influenza virus infection among outpatients enrolled in a test-negative study. Methods: From November 2018─May 2019, study sites in five states obtained serum and respiratory specimens from outpatients aged ≥18 years presenting with acute respiratory illness. Respiratory specimens were tested for influenza virus, and viral clades were identified by genomic sequencing. We measured influenza antibody titers against vaccine and circulating viruses by hemagglutination inhibition (HI), microneutralization (MN) and neuraminidase inhibition (NAI) assays. Percent of patients with HI, MN and NAI titers ≥10 and ≥40 were compared among patients with and without influenza-associated illness, and reduction in odds of confirmed influenza at increasing HI, MN and NAI antibody titers was estimated using logistic regression adjusting for influenza vaccination status and time since beginning of influenza season. Results: Among 175 patients with confirmed influenza virus infection, including 112 with influenza A(H1N1)pdm09 and 63 with A(H3N2) (44 clade 3C.3a), and 130 test-negative control patients, higher antibody titers against influenza hemagglutinin or neuraminidase proteins at enrollment were associated with lower odds of influenza virus infection. HI and MN antibody titers against circulating viruses were more strongly associated with protection than titers against vaccine reference viruses. Odds of A(H1N1)pdm09 infection were 44% and 54% lower for each two-fold increase in A(H1N1)pdm09 HI or NAI titer, respectively. Odds of A(H3N2) infection were 46% and 30% lower, respectively, for each two-fold increase in MN or NAI titer against circulating A(H3N2) virus clade. NAI titers were independently associated with lower odds of influenza A(H1N1)pdm09 and A(H3N2) after controlling for HI titer. Conclusion: Higher influenza antibody titers against circulating viruses were associated with lower likelihood of influenza virus infection among adult patients with acute respiratory illness. SUMMARY: From November 2018─May 2019, we assessed the association between antibody concentrations during acute illness and laboratory-confirmed influenza among adult patients enrolled in a test-negative study in five US states. We found that higher influenza antibody titers were associated with lower likelihood of symptomatic influenza virus infection.
- Open Access
Influenza Vaccine Effectiveness Against Pediatric Deaths: 2016–2025
BACKGROUND AND OBJECTIVES: Seasonal influenza vaccination has been shown to reduce the risk of influenza and severe complications among children 6 months and older. Since 2010, reported numbers of influenza-associated pediatric deaths among children aged <18 years have ranged from 37 during the 2011–2012 season to 289 during 2024–2025. We estimated influenza vaccine effectiveness (VE) against pediatric death from 2016–2017 through 2024–2025. METHODS: We conducted a case-cohort analysis comparing current season influenza vaccination status among reported influenza-associated pediatric deaths with survey estimates of influenza vaccination coverage in pediatric age groups. Underlying medical conditions and current seasonal influenza vaccination were obtained from surveillance case reports. We estimated vaccination odds ratios (OR) and 95% confidence intervals (CI) from logistic regression comparing influenza vaccination among children who died with vaccination coverage in comparison cohorts. VE was calculated as (1 – OR) × 100. RESULTS: From August 2016 through July 2025, 1234 laboratory-confirmed influenza-associated pediatric deaths were reported among children aged 6 months--17 years. Of 1086 reported deaths including influenza vaccination information, 124 (23%) of 530 children with underlying medical conditions and 70 (13%) of 556 children without known conditions were fully vaccinated against influenza. Average influenza vaccination coverage in survey cohorts was 49%. VE was 80% (95% CI, 75% to 84%) overall, 77% (95% CI, 71% to 82%) among children with underlying medical conditions and 87% (95% CI, 84% to 89%) among children without known conditions. CONCLUSIONS: Influenza vaccination reduced risk of fatal influenza among children with or without known underlying medical conditions.
Open AccessInfluenza Vaccine Effectiveness Against Pediatric Deaths: 2016–2025
BACKGROUND AND OBJECTIVES: Seasonal influenza vaccination has been shown to reduce the risk of influenza and severe complications among children 6 months and older. Since 2010, reported numbers of influenza-associated pediatric deaths among children aged <18 years have ranged from 37 during the 2011–2012 season to 289 during 2024–2025. We estimated influenza vaccine effectiveness (VE) against pediatric death from 2016–2017 through 2024–2025. METHODS: We conducted a case-cohort analysis comparing current season influenza vaccination status among reported influenza-associated pediatric deaths with survey estimates of influenza vaccination coverage in pediatric age groups. Underlying medical conditions and current seasonal influenza vaccination were obtained from surveillance case reports. We estimated vaccination odds ratios (OR) and 95% confidence intervals (CI) from logistic regression comparing influenza vaccination among children who died with vaccination coverage in comparison cohorts. VE was calculated as (1 – OR) × 100. RESULTS: From August 2016 through July 2025, 1234 laboratory-confirmed influenza-associated pediatric deaths were reported among children aged 6 months--17 years. Of 1086 reported deaths including influenza vaccination information, 124 (23%) of 530 children with underlying medical conditions and 70 (13%) of 556 children without known conditions were fully vaccinated against influenza. Average influenza vaccination coverage in survey cohorts was 49%. VE was 80% (95% CI, 75% to 84%) overall, 77% (95% CI, 71% to 82%) among children with underlying medical conditions and 87% (95% CI, 84% to 89%) among children without known conditions. CONCLUSIONS: Influenza vaccination reduced risk of fatal influenza among children with or without known underlying medical conditions.
- 3 December 2025
- Published by Oxford University Press (OUP) in The Journal of Infectious Diseases
Improved Immune Response Against Influenza A Viruses With Receipt of a Recombinant Influenza Vaccine in Healthcare Personnel With Prior Low Antibody Response to Egg-Based Influenza Vaccines, Israel, 2019–2020
Background: Adult studies have shown that quadrivalent recombinant influenza vaccines (RIV4) induce a higher antibody response than quadrivalent egg-based inactivated influenza vaccines (IIV4). Methods: Healthcare personnel (HCP) from a 2018–2019 cohort study that assessed IIV4 immunogenicity in Israel were recruited into a 2019–2020 randomized trial of RIV4 and IIV4. 2018–2019 low titer low responders (LTLRs) had pre-vaccination hemagglutination inhibition antibody titers ≤1:40 and <4-foldrise post-vaccination. We assessed whether RIV4 versus IIV4 receipt in the 2019–2020 season improved response among 2018–2019 LTLRs using logistic regression adjusted for employment hospital. Results: Of 228 HCP classified as 2018–2019 LTLRs, 2019–2020 RIV4 recipients were 3.6 (95% CI: 1.2–11.4) and 8.3 (95% CI: 3.0–26.3) times as likely to become a non-LTLR against influenza A(H1N1)pdm09 and cell-derived A(H3N2) vaccine components compared to IIV4 recipients. Conclusions: RIV4 had improved immunogenicity against influenza A viruses among previously classified low vaccine responder HCP, highlighting how recombinant influenza vaccines could improve antibody responses against influenza A for HCP at risk for poor influenza antibody response.
- 3 December 2025
- Published by Oxford University Press (OUP) in The Journal of Infectious Diseases
Improved Immune Response Against Influenza A Viruses With Receipt of a Recombinant Influenza Vaccine in Healthcare Personnel With Prior Low Antibody Response to Egg-Based Influenza Vaccines, Israel, 2019–2020
Background: Adult studies have shown that quadrivalent recombinant influenza vaccines (RIV4) induce a higher antibody response than quadrivalent egg-based inactivated influenza vaccines (IIV4). Methods: Healthcare personnel (HCP) from a 2018–2019 cohort study that assessed IIV4 immunogenicity in Israel were recruited into a 2019–2020 randomized trial of RIV4 and IIV4. 2018–2019 low titer low responders (LTLRs) had pre-vaccination hemagglutination inhibition antibody titers ≤1:40 and <4-foldrise post-vaccination. We assessed whether RIV4 versus IIV4 receipt in the 2019–2020 season improved response among 2018–2019 LTLRs using logistic regression adjusted for employment hospital. Results: Of 228 HCP classified as 2018–2019 LTLRs, 2019–2020 RIV4 recipients were 3.6 (95% CI: 1.2–11.4) and 8.3 (95% CI: 3.0–26.3) times as likely to become a non-LTLR against influenza A(H1N1)pdm09 and cell-derived A(H3N2) vaccine components compared to IIV4 recipients. Conclusions: RIV4 had improved immunogenicity against influenza A viruses among previously classified low vaccine responder HCP, highlighting how recombinant influenza vaccines could improve antibody responses against influenza A for HCP at risk for poor influenza antibody response.
- 16 October 2025
- Published by Oxford University Press (OUP) in Clinical Infectious Diseases
- Vol. 83 (2) , 289-302
Absolute and Relative Effectiveness of Cell Culture–Based and Egg–Based Quadrivalent Inactivated Influenza (Flu) Vaccine Products From the 2014–2015 to 2018–2019 Seasons, US Flu VE Network
Background: Estimates of the annual effectiveness of influenza vaccination combine multiple vaccine types. Reports of brand/product-specific vaccine effectiveness (VE) of egg-based and cell culture–based quadrivalent inactivated influenza vaccines (IIV4 and ccIIV4, respectively) are limited. Methods: Using an observational test-negative study design, we compared the effectiveness of selected IIV4 and ccIIV4 products among outpatients enrolled in the US Influenza Vaccine Effectiveness (Flu VE) Network from 2014–2015 to 2018–2019. We used multivariable logistic regression to estimate the product-specific and age group–specific absolute VE and relative VE (rVE) of recommended, age-appropriate vaccines against symptomatic laboratory-confirmed outpatient influenza. The rVE of ccIIV4 versus IIV4 products was estimated during 2 seasons from 2017–2019 among participants aged ≥4 years. Results: Pooling data from 5 influenza seasons when 18% and 15% of vaccinated patients had received Fluarix Quadrivalent or Fluzone Quadrivalent IIV4, respectively, the VE against influenza was 32% for Fluarix and 37% for Fluzone. Pooling 2 seasons when 11% and 28% of vaccinated patients had received ccIIV4 (Flucelvax Quadrivalent) and IIV4 (FluLaval Quadrivalent), respectively, the VE against influenza for each product was 30%. The absolute VE compared with unvaccinated patients was lowest against influenza A(H3N2) compared with that against A(H1N1)pdm09 and each B lineage; VE point estimates were lowest among patients aged ≥50 years compared with 2 younger age groups. The rVE estimates were not statistically significant, indicating similar protection across vaccine products. Conclusions: Comparisons of influenza vaccine products over multiple seasons showed benefit of both IIV4 and ccIIV4 against symptomatic laboratory-confirmed outpatient influenza, with similar absolute and relative levels of protection provided by each product.
- 16 October 2025
- Published by Oxford University Press (OUP) in Clinical Infectious Diseases
- Vol. 83 (2) , 289-302
Absolute and Relative Effectiveness of Cell Culture–Based and Egg–Based Quadrivalent Inactivated Influenza (Flu) Vaccine Products From the 2014–2015 to 2018–2019 Seasons, US Flu VE Network
Background: Estimates of the annual effectiveness of influenza vaccination combine multiple vaccine types. Reports of brand/product-specific vaccine effectiveness (VE) of egg-based and cell culture–based quadrivalent inactivated influenza vaccines (IIV4 and ccIIV4, respectively) are limited. Methods: Using an observational test-negative study design, we compared the effectiveness of selected IIV4 and ccIIV4 products among outpatients enrolled in the US Influenza Vaccine Effectiveness (Flu VE) Network from 2014–2015 to 2018–2019. We used multivariable logistic regression to estimate the product-specific and age group–specific absolute VE and relative VE (rVE) of recommended, age-appropriate vaccines against symptomatic laboratory-confirmed outpatient influenza. The rVE of ccIIV4 versus IIV4 products was estimated during 2 seasons from 2017–2019 among participants aged ≥4 years. Results: Pooling data from 5 influenza seasons when 18% and 15% of vaccinated patients had received Fluarix Quadrivalent or Fluzone Quadrivalent IIV4, respectively, the VE against influenza was 32% for Fluarix and 37% for Fluzone. Pooling 2 seasons when 11% and 28% of vaccinated patients had received ccIIV4 (Flucelvax Quadrivalent) and IIV4 (FluLaval Quadrivalent), respectively, the VE against influenza for each product was 30%. The absolute VE compared with unvaccinated patients was lowest against influenza A(H3N2) compared with that against A(H1N1)pdm09 and each B lineage; VE point estimates were lowest among patients aged ≥50 years compared with 2 younger age groups. The rVE estimates were not statistically significant, indicating similar protection across vaccine products. Conclusions: Comparisons of influenza vaccine products over multiple seasons showed benefit of both IIV4 and ccIIV4 against symptomatic laboratory-confirmed outpatient influenza, with similar absolute and relative levels of protection provided by each product.
- 9 October 2025
- Published by Oxford University Press (OUP) in Clinical Infectious Diseases
Approaches to Comparing Influenza Vaccine Effectiveness to Guide Potential Preferential Product Recommendations
New influenza vaccine products might be licensed in coming years. Ideally, these vaccines would generate more broadly cross-reactive and longer-lasting protection than those currently licensed. Recommendations for the use of and potential preference for new influenza vaccines should be informed by absolute and comparative effectiveness evaluations. Absolute vaccine effects are commonly evaluated pre- and postlicensure, but more complex comparative evaluations have special considerations discussed in this Viewpoint. Relative vaccine effectiveness (rVE) can be assessed in clinical trials, cluster-randomized trials, and a variety of observational designs. Cluster-randomized trials have reduced potential for bias compared to observational studies, but operational barriers may limit feasibility. Observational rVE studies may utilize prospectively collected data or real-world evidence from large healthcare databases. Advantages of observational rVE studies include timeliness and lower cost, but uptake of novel influenza vaccines that is low and variable by age, health status, and other characteristics is a major challenge.
- 9 October 2025
- Published by Oxford University Press (OUP) in Clinical Infectious Diseases
Approaches to Comparing Influenza Vaccine Effectiveness to Guide Potential Preferential Product Recommendations
New influenza vaccine products might be licensed in coming years. Ideally, these vaccines would generate more broadly cross-reactive and longer-lasting protection than those currently licensed. Recommendations for the use of and potential preference for new influenza vaccines should be informed by absolute and comparative effectiveness evaluations. Absolute vaccine effects are commonly evaluated pre- and postlicensure, but more complex comparative evaluations have special considerations discussed in this Viewpoint. Relative vaccine effectiveness (rVE) can be assessed in clinical trials, cluster-randomized trials, and a variety of observational designs. Cluster-randomized trials have reduced potential for bias compared to observational studies, but operational barriers may limit feasibility. Observational rVE studies may utilize prospectively collected data or real-world evidence from large healthcare databases. Advantages of observational rVE studies include timeliness and lower cost, but uptake of novel influenza vaccines that is low and variable by age, health status, and other characteristics is a major challenge.
- Open Access
- 12 September 2025
- Published by Elsevier in American Journal of Preventive Medicine
- Vol. 70 (1) , 108096
Does Home COVID-19 Testing Bias COVID-19 Vaccine Effectiveness Estimates?
- 12 September 2025
- Published by Elsevier in American Journal of Preventive Medicine
- Vol. 70 (1) , 108096
Open AccessDoes Home COVID-19 Testing Bias COVID-19 Vaccine Effectiveness Estimates?